Table 1 Demographic and clinicopathologic characteristics in the development cohort
From: Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
Variable | Value |
|---|---|
Sex, n (%) | |
 Male | 132 (46.6) |
 Female | 151 (53.4) |
Age, median (range) | 65.4 y (27.5–90.2 y) |
Race/ethnicity, n (%) | |
 Caucasian | 215 (76.0) |
 Asian | 27 (9.5) |
 Black | 19 (6.7) |
 Hispanic | 21 (7.4) |
 Unknown | 1 (0.3) |
Smoking status, n (%) | |
 Never-smoker | 64 (22.6) |
 Former smoker | 136 (48.1) |
 Current smoker | 82 (29.0) |
 Unknown | 1 (0.3) |
Vital status, n (%) | |
 Alive | 172 (60.8) |
 Deceased | 111 (39.2) |
Molecular platform, n (%) | |
 NGS | 218 (77.0) |
 PCRa | 55 (19.5) |
 Not done | 10 (3.5) |
Molecular subtype, n (%) (n = 233) | |
 sTRU – EGFR (%) | 34 (14.6) |
 sPP – KRAS (%) | 43 (18.5) |
 sPI – TP53 (%) | 46 (19.7) |
 Co-mutation | 60 (25.8) |
 EGFR/TP53 | 26 (11.2) |
 KRAS/ TP53 | 34 (14.6) |
 Non-TRUPPPI | 21 (9.0) |
 No mutations detected by NGS | 29 (12.4) |
FISH results, n (%) | |
 Negative | 250 (88.3) |
 Positive | 24 (8.5) |
 ALK | 16 (5.7) |
 ROS1 | 1 (0.4) |
 RET | 2 (0.7) |
 MET | 5 (1.8) |
 Indeterminate | 9 (3.2) |
 Aneuploidy | 193 (68.2) |